Search results
Results from the WOW.Com Content Network
Clomipramine may interact with a number of different medications, including the monoamine oxidase inhibitors which include isocarboxazid, moclobemide, phenelzine, selegiline and tranylcypromine, antiarrhythmic agents (due to the effects of TCAs like clomipramine on cardiac conduction.
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as effective antidepressants , especially for treatment-resistant depression and atypical depression . [ 1 ]
1.3 N06AF Monoamine oxidase inhibitors, non-selective. ... N06AA04 Clomipramine N06AA05 Opipramol N06AA06 Trimipramine N06AA07 Lofepramine N06AA08 Dibenzepin
11 Monoamine oxidase inhibitors (MAOIs) Toggle Monoamine oxidase inhibitors (MAOIs) subsection. 11.1 Irreversible. ... Clomipramine (Anafranil) Desipramine (Norpramin
Monoamine oxidase A and B share roughly 70% of their structure and both have substrate binding sites that are predominantly hydrophobic. Two tyrosine residues (398, 435 within MAO-B , 407 and 444 within MAO-A ) in the binding pocket that are commonly involved in inhibitor activity have been hypothesized to be relevant to orienting substrates ...
They are not considered addictive and are somewhat preferable to the monoamine oxidase inhibitors (MAOIs). The side effects of the TCAs usually come to prominence before the therapeutic benefits against depression and/or anxiety do, and for this reason, they may potentially be somewhat dangerous, as volition can be increased, possibly giving ...
Tranylcypromine, sold under the brand name Parnate among others, [1] is a monoamine oxidase inhibitor (MAOI). [4] [7] More specifically, tranylcypromine acts as nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO).
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. [1] The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.